Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study — Eduard Vieta (2010) | RDL Network
Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study
As an open-label extension study with a low completion rate, a conservative interpretation of the findings is warranted. Additionally, the study population was not randomly selected but chosen at the discretion of the investigator, and patients did not maintain therapeutic levels of their mood stabiliser consistently.
Iría Grande, Inês Chendo, Benício N. Frey, Keila M. Ceresér, Laura Stertz, Gabriela Delevati Colpo, GR Fries, Angelo Batista da Cunha, Eduard Vieta, Flávio Kapczinski
Féline P B Kroon, Marion C Kortekaas, Annelies Boonen, Stefan Böhringer, M. Reijnierse, Frits R. Rosendaal, N. Riyazi, M. Starmans, Franktien Turkstra, J. van Zeben, Cornelia F Allaart, M. Kloppenburg
Eduard Vieta, Núria Cruz, Javier García‐Campayo, Rosario de Arce, José Manuel Crespo, Vicenç Vallès, Josefina Pérez‐Blanco, Ernesto Roca, J.M. Olivares, Ángel Moríñigo, Raul Fernández-Villamor, Mercé Comes
Frank Smithuis, Moe Kyaw Kyaw, Ohn Phe, Khin Zarli Aye, Linn Htet, M. Barends, Niklas Lindegårdh, Thida Singtoroj, Elizabeth A. Ashley, Saw Lwin, Kasia Stepniewska, Sir Nicholas White
Discussion(0)
No comments yet. Be the first to comment.